Chemotherapy and targeted agents for thymic malignancies

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 685-695

  Girard, Nicolas ^a,b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

chemotherapy; EGFR; KIT SCFR; mast stem cell growth factor receptor; octreotide; radiotherapy; surgery; targeted therapy; thymic carcinoma; thymoma; VEGFR

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; METHYLPREDNISOLONE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; PREDNISONE; SORAFENIB; SUNITINIB; UNINDEXED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; DRUG POTENCY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; POSTOPERATIVE CARE; PREOPERATIVE CARE; REVIEW; THYMECTOMY; THYMOMA; THYMUS CANCER; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CONSOLIDATION CHEMOTHERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; THYMUS NEOPLASMS;

EID: 84861323222     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.29     Document Type: Review

References (99)

1. Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: a focus on current therapeutic management. J. Thorac. Oncol. 4(1), 119-126 (2009).
2. WHO histological classification of tumours of the thymus. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France, 146 (2004).
3. Girard N. Thymic tumors: relevant molecular data in the clinic. J. Thorac. Oncol. 5(10S4), S291-S295 (2010).
4. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR Jr. Thymic carcinoma: state of the art review. Int. J. Radiat. Oncol. Biol. Phys. 59(3), 654-664 (2004).
5. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 48(11), 2485-2492 (1981).
6. Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J. Thorac. Oncol. 6(7 S3), S1710-S1716 (2011).
7. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann. Thorac. Surg. 76(3), 878-884 (2003).
8. Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy definitions and policies for thymic malignancies. J. Thorac. Oncol. 6(7S3), S1749-S1755 (2011).
9. Girard N, Shen R, Guo T et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin. Cancer Res. 15(122), 6790-6799 (2009).
10. Girard N, Teruya-Feldstein J, Payabyab EC et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J. Thorac. Oncol. 5(9), 1439-1446 (2010).
11. Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J. Thorac. Oncol. 6(7S3), S1698-S1704 (2011).
12. Macchiarini P, Chella A, Ducci F et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68(4), 706-713 (1991).
13. Berruti A, Borasio P, Roncari A, Gorzegno G, Mossetti C, Dogliotti L. Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients. Ann. Oncol. 4(5), 429-431 (1993).
14. Rea F, Sartori F, Loy M et al. Chemotherapy and operation for invasive thymoma. J. Thorac. Cardiovasc. Surg. 106(3), 543-549 (1993).
15. Berruti A, Borasio P, Gerbino A et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br. J. Cancer 81(5), 841-845 (1999).
16. Venuta F, Rendina EA, Longo F et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann. Thorac. Surg. 76(6), 1866-1872 (2003).
17. Bretti S, Berruti A, Loddo C et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 44(1), 69-77 (2004).
18. Kim ES, Putnam JB, Komaki R et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44(3), 369-379 (2004).
19. Lucchi M, Ambrogi MC, Duranti L et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann. Thorac. Surg. 79(6), 1840-1844 (2005).
20. Jacot W, Quantin X, Valette S et al. Multimodality treatment program in invasive thymic epithelial tumor. Am. J. Clin. Oncol. 28(1), 5-7 (2005).
21. Yokoi K, Matsuguma H, Nakahara R et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J. Thorac. Oncol. 2(1), 73-78 (2007).
22. Kunitoh H, Tamura T, Shibata T et al. A Phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br. J. Cancer 103(1), 6-11 (2010).
23. Loehrer PJ Sr, Chen M, Kim K et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J. Clin. Oncol. 15(9), 3093-3099 (1997).
24. Wright CD, Choi NC, Wain JC, Mathisen DJ, Lynch TJ, Fidias P. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVa thymic tumors. Ann. Thorac. Surg. 85(2), 385-389 (2008).
25. Fuller CD, Housman DM, Thomas CR. Radiotherapy for thymoma and thymic carcinoma. Hematol. Oncol. Clin. North. Am. 22(3), 489-507 (2008).
26. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am. J. Clin. Oncol. 27(1), 68-72 (2004).
27. Giaccone G, Wilmink H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma: a decade experience at a single institution. Am. J. Clin. Oncol. 29(4), 336-344 (2006).
28. Huang J, Rizk NP, Travis WD et al. Feasibility of multimodality therapy including extended resections in stage IVa thymoma. J. Thorac. Cardiovasc. Surg. 134(6), 1477-1483 (2007).
29. Cowen D, Richaud P, Mornex F et al. Thymoma: results of a multicentric retrospective series of 149 nonmetastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiother. Oncol. 34(1), 9-16 (1995).
30. Kitami A, Suzuki T, Kamio Y, Suzuki S. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Jpn J. Clin. Oncol. 31(12), 601-604 (2001).
31. Shin DM, Walsh GL, Komaki R et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann. Intern. Med. 129(2), 100-104 (1998).
32. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 Phase II trial of cisplatin in metastatic or recurrent thymoma. Am. J. Clin. Oncol. 16(4), 342-345 (1993).
33. Highley MS, Underhill CR, Parnis FX et al. Treatment of invasive thymoma with single-agent ifosfamide. J. Clin. Oncol. 17(9), 2737-2744 (1999).
34. Loehrer PJ, Yiannoutsos CT, Dropcho S et al. A Phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol. 24(18S), 7079 (2006).
35. Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy of invasive thymoma. J. Clin. Oncol. 8(8), 1419-1423 (1990).
36. Loehrer PJ Sr, Kim K, Aisner SC et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J. Clin. Oncol. 12(6), 1164-1168 (1994).
37. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 14(3), 814-820 (1996).
38. Loehrer PJ Sr, Jiroutek M, Aisner S et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91(11), 2010-2015 (2001).
39. Lemma GL, Lee JW, Aisner SC et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J. Clin. Oncol. 29(15), 2060-2065 (2011).
40. Palmieri G, Merola G, Federico P et al. Preliminary results of Phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann. Oncol. 21(6), 1168-1172 (2010).
41. Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 74(3), 492-496 (2011).
42. Grassin F, Paleiron N, André M et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J. Thorac. Oncol. 5(6), 893-897 (2010).
43. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome measures for thymic malignancies. J. Thorac. Oncol. 6(7 Suppl. 3), S1691-S1697 (2011).
44. Lara PN Jr, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest 110(4), 1115-1117 (1996).
45. Mygland A, Vincent A, Newsom-Davis J et al. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch. Neurol. 57(4), 527-531 (2000).
46. Loehrer PJ Sr, Wang W, Johnson DH. Eastern Cooperative Oncology Group Phase II Trial. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J. Clin. Oncol. 22(2), 293-299 (2004).
47. Palmieri G, Montella L, Martignetti A et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94(5), 1414-1420 (2002).
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
49. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008).
50. Shedden K, Taylor JM, Enkemann SA et al. Gene expression-based survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat. Med. 14(8), 822-827 (2008).
51. Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171), 893-898 (2007).
52. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
53. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heel of cancer. Science 297(5578), 63-64 (2002).
54. Breinig M, Mayer P, Harjung A et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin. Cancer Res. 17(8), 2237-2249 (2011).
55. Kuhn E, Wistuba II. Molecular pathology of thymic epithelial neoplasms. Hematol. Oncol. Clin. North Am. 22(3), 443-455 (2008).
56. Suzuki E, Sasaki H, Kawano O et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn. J. Clin. Oncol. 36(6), 351-356 (2006).
57. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103(3), 630-636 (2005).
58. Yoh K, Nishiwaki Y, Ishii G et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62(3), 316-320 (2008).
59. Yamaguchi H, Soda H, Kitazaki T, Tsukamoto K, Hayashi T, Kohno S. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 52(2), 261-262 (2006).
60. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. J. Clin. Oncol. 23(Suppl. 16), 7068 (2005).
61. Suzuki M, Chen H, Shigematsu H et al. Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol. Rep. 14(6), 1621-1624 (2005).
62. Sasaki H, Yano M, Fujii Y. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. J. Thorac. Oncol. 5(10), 1715-1716 (2010).
63. Bedano PM, Perkins S, Burns M et al. A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J. Clin. Oncol. 15(Suppl.), 19087 (2008).
64. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol. 8(5), 449-450 (2007).
65. Palmieri G, Marino M, Salvatore M et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci. 12, 757-761 (2007).
66. Christodoulou C, Murray S, Dahabreh J et al. Response of malignant thymoma to erlotinib. Ann. Oncol. 19(7), 1361-1362 (2008).
67. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J. Cancer. Res. Clin. Oncol. 130(4), 222-224 (2004).
68. Ströbel P, Bargou R, Wolff A et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br. J. Cancer 103(2), 196-200 (2010).
69. Ströbel P, Hartmann M, Jakob A et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N. Engl. J. Med. 350(25), 2625-2626 (2004).
70. Li XF, Chen Q, Huang WX, Ye YB. Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med. Oncol. 26(2), 157-160 (2009).
71. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (sorafenib) in a heavily pretreated metastatic thymic carcinoma. J. Thorac. Oncol. 4(6), 773-775 (2009).
72. Disel U,, Oztuzcu S, Besen AA et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71(1), 109-112 (2011).
73. Buti S, Donini M, Sergio P et al. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol. 29(33), e803-e805 (2011).
74. Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 26(33), 5352-5359 (2008).
75. Palmieri G, Marino M, Buonerba C et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother. Pharmacol. 69(2), 309-315 (2012).
76. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J. Thorac. Oncol. 4(10), 1270-1273 (2009).
77. Salter JT, Lewis D, Yiannoutsos C, Loehrer PJ, Risley L, Chiorean EG. Imatinib for the treatment of thymic carcinoma. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 8116).
78. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8(12), 915-928 (2008).
79. Gong Y, Yao E, Shen R et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4(10), e7273 (2009).
80. Zucali PA, Petrini I, Lorenzi E et al. Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 116(20), 4686-4695 (2010).
81. Haluska P, Shaw H, Batzel GN et al. Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer. Res. 13(19), 5834-5840 (2007).
82. Cimpean AM, Raica M, Encica S et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann. Anat. 190(3), 238-245 (2008).
83. Marino M, Piantelli M. Immunohistochemistry of thymic epithelial tumors as a tool in translational research. J. Thorac. Surg. Clin. 21(1), 33-46 (2011).
84. Tomita M, Matsuzaki Y, Edagawa M et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J. Thorac. Cardiovasc. Surg. 124(3), 493-498 (2002).
85. Sasaki H, Yukiue H, Kobayashi Y et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg. Today 31(11), 1038-1040 (2001).
86. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A Phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 3599).
87. Chuah C, Lim TH, Lim AS et al. Dasatinib induces a response in malignant thymoma. J. Clin. Oncol. 24(34), e56-e58 (2006).
88. Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbutt NC. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta. Oncol. 48(4), 619-621 (2009).
89. Giaccone G, Rajan A, Berman A et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J. Clin. Oncol. 29(15), 2052-2059 (2011).
90. Hirabayashi H, Fujii Y, Sakaguchi M et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int. J. Cancer 73(5), 639-644 (1997).
91. Tagawa T, Ohta M, Kuwata T, Awaya H, Ishida T. S-1 plus cisplatin chemotherapy with concurrent radiation for thymic basaloid carcinoma. J. Thorac. Oncol. 5(4), 572-573 (2010).
92. Okuma Y, Shimokawa T, Takagi Y et al. S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer 70(3), 357-363 (2010).
93. Kirkove C, Berghmans J, Noel H, van de Merckt J. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin. Oncol. (R. Coll. Radiol.) 4(1), 64-66 (1992).
94. Craven C, Reddy PK, Ringel SP, Rutherford RB. Effect of corticosteroids on the thymus in myasthenia gravis. Muscle Nerve 4(5), 425-428 (1981).
95. Yarom N, Zissin R, Apter S, Hertz M, Rahimi-Levene N, Gayer G. Rebound thymic enlargement on CT in adults. Int. J. Clin. Pract. 61(4), 562-568 (2007).
96. Aisner SC, Dahlberg S, Hameed MR et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J. Thoracic. Oncol. 5(6), 885-892 (2010).
97. Mineo TC, Ambrogi V, Baldi A, Pompeo E, Mineo D. Recurrent intrathoracic thymomas: potential prognostic importance of cell-cycle protein expression. J. Thorac. Cardiovasc. Surg. 138(1), 40-45 (2009).
98. Petrini I, Wang Y, Pineda M, Davis S, Giaccone G. O40.01 complete genome sequencing of a human B3 thymoma. J. Thorac. Oncol. 6(6), S452 (2011).
99. Kaira K, Serizawa M, Koh Y et al. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 74(3), 419-25 (2011).